CORDIS
EU research results

CORDIS

English EN
REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019

REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019

Objective

RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk groups. RESCEU brings together academia, national public health agencies and EFPIA with proven expertise and a strong track record in RSV research. The academic partners are leaders in RSV epidemiology, clinical RSV research, health economics, and vaccinology; and key opinion leaders with advisory roles in European and national public health bodies, health technology agencies and vaccine advisory groups. EFPIA participants (AZ, GSK, JPNV, Novavax, Pfizer, and SP) have active clinical research programmes to develop lead candidates for treatment and prevention of RSV in infants, adults and the elderly. As part of RESCEU, EFPIA participants will contribute expertise in a wide range of fields including infectious disease, clinical medicine, immunology, epidemiology, biostatistics, biomarker development, global health, and health economics. RESCEU’s aim is to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics. RESCEU aims to provide sustainable longer term impact on RSV disease burden and thus make a significant contribution to improved health and wellbeing in Europe.
The project will comprise 6 work packages. WP 1-3 will identify and marshal data from large-scale systematic reviews of epidemiological and cost studies, disease registries, linked routine (national) healthcare and claims datasets and will establish a framework for and assemble data from RSV surveillance in Europe to estimate RSV disease burden on health services and inform economic models.

Coordinator

THE UNIVERSITY OF EDINBURGH

Address

Old College, South Bridge
Eh8 9yl Edinburgh

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 4 181 125

Participants (17)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITEIT ANTWERPEN

Belgium

EU Contribution

€ 1 203 875

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 2 352 625

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 2 122 875

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain

EU Contribution

€ 1 093 750

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 863 125

SERVIZO GALEGO DE SAUDE

Spain

EU Contribution

€ 500 375

VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA

Finland

EU Contribution

€ 595 750

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

Netherlands

EU Contribution

€ 598 125

STATENS SERUM INSTITUT

Denmark

EU Contribution

€ 504 375

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 307 125

FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS

Italy

EU Contribution

€ 175 000

ASTRAZENECA AB

Sweden

PFIZER LIMITED

United Kingdom

GLAXOSMITHKLINE BIOLOGICALS SA

Belgium

SANOFI PASTEUR SA

France

JANSSEN PHARMACEUTICA NV

Belgium

NOVAVAX INC

United States

Project information

Grant agreement ID: 116019

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.

  • Overall budget:

    € 29 171 790

  • EU contribution

    € 14 498 125

Coordinated by:

THE UNIVERSITY OF EDINBURGH

United Kingdom